Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Magnevist
Drug ID BADD_D01345
Description A complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see pentetic acid), that is given to enhance the image in cranial and spinal MRIs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p706)
Indications and Usage For use with magnetic resonance imaging (MRI) in adults, and pediatric patients (2 years of age and older) to visualize lesions with abnormal vascularity in the brain (intracranial lesions), spine and associated tissues as well as lesions with abnormal vascularity in the head and neck. Also used to facilitate the visualization of lesions with abnormal vascularity in the body (excluding the heart).
Marketing Status Prescription
ATC Code V08CA01
DrugBank ID DB00789
KEGG ID D01707
MeSH ID D019786
PubChem ID 55466
TTD Drug ID D0RQ2W
NDC Product Code Not Available
Synonyms Gadolinium DTPA | DTPA, Gadolinium | Gadolinium Diethylenetriaminepenta-acetic Acid | Diethylenetriaminepenta-acetic Acid, Gadolinium | Gadolinium Diethylenetriaminepenta acetic Acid | Gadopentetic Acid | Gd-DTPA | Gd DTPA | Gadolinium DTPA Disodium Salt | Magnograf | Magnograf Enteral | Gadopentetate Dimeglumine | Dimeglumine, Gadopentetate | Gadolinium DTPA Dimeglumine Salt | Gadolinium DTPA Dimeglumine | Dimeglumine, Gadolinium DTPA | Magnevist | Magnevist Enteral
Chemical Information
Molecular Formula C28H54GdN5O20
CAS Registry Number 80529-93-7
SMILES CNCC(C(C(C(CO)O)O)O)O.CNCC(C(C(C(CO)O)O)O)O.C(CN(CC(=O)O)CC(=O)[O-])N(CCN(CC(=O) O)CC(=O)[O-])CC(=O)[O-].[Gd+3]
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Syncope24.06.02.012; 17.02.04.008; 02.01.02.008--
Tachycardia02.03.02.007--Not Available
Tachypnoea22.02.01.014--Not Available
Teething07.09.05.005--Not Available
Tension19.06.02.005--Not Available
Thirst14.03.02.007; 08.01.09.021--Not Available
Throat irritation22.02.05.013; 07.05.03.004--Not Available
Throat tightness19.01.02.005; 22.02.05.015--Not Available
Thrombophlebitis24.01.02.001--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Toothache07.09.06.001--
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 10.01.01.006; 11.07.01.006--
Tremor17.01.06.002--
Urethral disorder20.07.01.002--Not Available
Urinary incontinence20.02.02.010; 17.05.01.008--
Urinary tract disorder20.08.01.001--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Visual field defect17.17.01.001; 06.02.07.003--Not Available
Visual impairment06.02.06.008--Not Available
Vomiting07.01.07.003--
Wheezing22.03.01.009--
Musculoskeletal disorder15.03.01.004--Not Available
Hypoacusis04.02.01.006--
Localised oedema14.05.06.009; 08.01.07.011; 02.05.04.006--
Injection site coldness12.07.03.023; 08.02.03.023--Not Available
Deep vein thrombosis24.01.02.003--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Lymphatic disorder01.09.01.003--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Injection site swelling08.02.03.017; 12.07.03.018--Not Available
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages